Table of Contents
- the acceptability of data obtained from trials conducted outside the United States to the FDA in support of a BLA.
Risks Related to Commercialization of Our Product
If we are unable to establish effective marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if they are
approved, we may be unable to generate product revenues.
We currently do not have a commercial infrastructure for the marketing, sale and distribution of biological products. If approved, in
order to commercialize our products, we must build our marketing, sales and distribution capabilities or make arrangements with third parties to perform these services. We may not be successful in
doing so. If PRT-201 is approved by the FDA, we plan to build a specialty hospital sales force in the United States of approximately 75-100 representatives, supported by reimbursement specialists and
a medical affairs team. We may seek to further penetrate the U.S. market in the future by expanding our sales force or through collaborations with other pharmaceutical or biotechnology companies or
third party manufacturing and sales organizations. If approved for marketing outside the United States, we may commercialize outside the United States with our own specialty hospital sales force
and/or with a commercial partner.
a company we have no prior experience in the marketing, sale and distribution of biological products, and there are significant risks involved in the building and managing of a
commercial infrastructure. The establishment and development of our own sales force and related compliance plans to market any products we may develop will be expensive and time consuming and could
delay any product launch, and we may not be able to successfully develop this capability. We, or our future collaborators, will have to compete with other companies to recruit, hire, train, manage and
retain marketing and sales personnel. In the event we are unable to develop a marketing and sales infrastructure, we may not be able to commercialize PRT-201 or any additional product candidates,
which would limit our ability to generate product revenues. Our ability to generate product revenues would be impaired by:
- our inability to recruit, train, manage and retain adequate numbers of effective sales and marketing personnel;
- the inability of sales
personnel to obtain access to vascular surgeons or persuade adequate numbers of vascular surgeons
to use PRT-201 or any additional product candidates;
- our inability to effectively oversee a geographically dispersed sales and marketing team; and
- unforeseen costs and expenses associated with creating an independent sales and marketing organization.
our current plan is to hire most of our sales and marketing personnel only if PRT-201 is approved by the FDA, we will incur expenses prior to product launch in recruiting this
sales force and developing a marketing and sales infrastructure. If the commercial launch of PRT-201 is delayed as a result of FDA requirements or other reasons, we would incur these expenses prior to
being able to realize any revenue from sales of PRT-201. Even if we are able to effectively hire a sales force and develop a marketing and sales infrastructure, our sales force and marketing teams may
not be successful in commercializing PRT-201 or any additional product candidates.
the event we are unable to hire a sales force or collaborate with a third-party marketing and sales organization to commercialize any approved product candidates outside the United
States, our ability to generate product revenues may be limited. To the extent we rely on third parties to commercialize any products for which we obtain regulatory approval, we may receive less
revenues than if we commercialized these products ourselves. In addition, we would have less control over the sales efforts of any other third parties involved in our commercialization efforts.